Research

Hormonal

Tirzepatide significantly reduces urine albumin-to-creatinine ratio (UACR) compared to placebo and insulin, indicating improved renal microvascular health, while maintaining a neutral effect on estimated glomerular filtration rate (eGFR) over short-term follow-up.

If you have Type 2 Diabetes or obesity, Tirzepatide (5-15 mg weekly) significantly lowers albuminuria (a marker of kidney stress) compared to placebo or insulin, without negatively impacting your kidney's filtration rate over 6-18 months. This suggests renal protection, particularly for those with existing high albuminuria. However, long-term data is still needed.

ModerateSupportsLOW confidence
Tirzepatide 10 mg and 15 mg, but not 5 mg, was superior to placebo in percent reductions of UACR... Tirzepatide, at all doses, outperformed insulin in percent reductions of UACR... The CFB in eGFR with all doses of tirzepatide was comparable... vs insulin.
A B Kamrul-Hasan et al. · World Journal of Diabetes · 2024

Why this rating

Meta-analysis of 15 RCTs, but GRADE certainty is mostly 'low' or 'very low' due to heterogeneity and short duration.

Source

Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis

A B Kamrul-Hasan et al. · World Journal of Diabetes · 2024

DOI 10.4239/wjd.v16.i2.101282

Meta-analysis · 15 studiesCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →